A USA-based venture capital fund is currently making investments out of a $150-million-dollar fund. The firm is looking to make 15 additional investments with allocations generally in the $1-3 million range. The firm is looking to make equity investments and is open to investing in companies globally.
The firm is interested in therapeutic companies developing small molecules for inflammation, infectious and autoimmune disease and stays away from biologics, cell and gene therapy. The firm is also interested in digital health and mobile health services, AI in healthcare, B2B2C medical devices. The firm is looking for companies with some level of proof-of-concept data either in vivo or in vitro up until Phase II of clinical trials. As for digital health, the firm is looking for scalable SAAS models, novel types of healthcare delivery, point-of-care diagnostics and patient’s self-management tools.
The firm is willing to work with incomplete management teams, often working with IP that has just recently spun out of a university. The firm is willing and able to act as a lead or co-investor in financing rounds.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 